<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927262</url>
  </required_header>
  <id_info>
    <org_study_id>2215-CL-0302</org_study_id>
    <secondary_id>2016-001643-39</secondary_id>
    <nct_id>NCT02927262</nct_id>
  </id_info>
  <brief_title>A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare relapse-free survival (RFS) between subjects with&#xD;
      FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) acute myeloid leukemia&#xD;
      (AML) in first complete remission (CR1) and who are randomized to receive gilteritinib or&#xD;
      placebo beginning after completion of induction/consolidation chemotherapy for a two-year&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in CR1 will be approached for this study after induction/consolidation therapy is&#xD;
      complete and a decision not to proceed with transplantation is made or a suitable donor could&#xD;
      not be identified. Subjects will be randomized in a 2:1 ratio to receive gilteritinib or&#xD;
      placebo. Subjects will enter the screening period up to 14 days prior to the start of&#xD;
      treatment. Subjects will be administered treatment over continuous 28-day cycles.&#xD;
      Gilteritinib or placebo will be given daily for up to 2 years. After treatment&#xD;
      discontinuation, subjects will have a 30-day follow-up visit for safety, after which the&#xD;
      subjects will enter the long-term follow up period for collection of subsequent AML&#xD;
      treatment, remission status, and survival (cause of death and date of death). Subjects will&#xD;
      be contacted every 3 months until final database lock. Study drug will not be provided during&#xD;
      the follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free Survival (RFS)</measure>
    <time_frame>Up to 52 months</time_frame>
    <description>RFS is defined as the time from the date of randomization until the date of documented relapse or death from any cause, whichever occurs first. Relapse after Complete Remission (CR) (including Complete Remission with incomplete Platelet recovery (CRp) and Complete Remission with incomplete hematologic recovery (CRi)), is defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised International Working Group (IWG) criteria. Relapse events will be adjudicated by an independent review committee and will be used in the efficacy assessments, unless specifically stated otherwise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>OS is defined as the time from the date of randomization until the date of death from any cause. For surviving subjects, non-events will be censored at the date of last known date alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>EFS is defined as the time from the date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Up to 54 months</time_frame>
    <description>MRD will be measured from bone marrow samples. FLT3/ITD mutation ratio will be measured in relation to total FLT3. Changes in FLT3/ITD mutation ratio will be compared with baseline/screening samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs and/or adverse events related to treatment</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by electrocardiograms (ECGs)</measure>
    <time_frame>Up to 54 months</time_frame>
    <description>The 12-lead ECGs will be recorded in triplicate (3 separate ECGs, 10 minutes resting prior to first ECG and at least 5 minutes apart per time point) and transmitted electronically for central reading. The mean of the triplicate ECG from central read should be used for all final treatment decisions and AE reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical exam abnormalities and/or adverse events related to treatment</measure>
    <time_frame>Up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status score</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ECOG performance status measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2= Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5=Dead.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation</condition>
  <arm_group>
    <arm_group_label>ASP2215</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with ASP2215 once daily (continuously for up to 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be treated with matching placebo tablets once daily (continuously for up to 2 years).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gilteritinib</intervention_name>
    <description>Tablet to be taken orally once daily.</description>
    <arm_group_label>ASP2215</arm_group_label>
    <other_name>ASP2215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet to be taken orally once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is considered an adult according to local regulation at the time of obtaining&#xD;
             consent form (ICF).&#xD;
&#xD;
          -  Subject consents to allow access to subject's diagnostic bone marrow aspirate or&#xD;
             peripheral blood sample and/or the DNA derived from that sample, if available, that&#xD;
             may be used to validate a companion diagnostic test for gilteritinib.&#xD;
&#xD;
          -  Subject has confirmed morphologically documented AML, excluding acute promyelocytic&#xD;
             leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR&#xD;
             will be defined as &lt; 5% blasts in the bone marrow with no morphologic characteristics&#xD;
             of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of&#xD;
             extramedullary disease such as central nervous system involvement or granulocytic&#xD;
             sarcoma.&#xD;
&#xD;
          -  Subject will not proceed with transplantation as either a decision not to proceed with&#xD;
             transplantation has been made either on the recommendation of the treating physician&#xD;
             or by the patient or a suitable donor could not be identified.&#xD;
&#xD;
          -  Subject is &lt; 2 months from the start of the last cycle of consolidation and should&#xD;
             have completed the recommended number of consolidations per local practice.&#xD;
&#xD;
          -  Subject has had no use of investigational agents, with the exception of FLT3&#xD;
             inhibiting agents during induction and/or consolidation therapy, within the prior 4&#xD;
             weeks.&#xD;
&#xD;
          -  Subject has had presence of the FLT3/ITD activating mutation in the bone marrow or&#xD;
             peripheral blood as determined by the local institution at diagnosis.&#xD;
&#xD;
          -  Subject has an ECOG performance status 0 to 2.&#xD;
&#xD;
          -  Subject must meet the following criteria as indicated on the clinical laboratory&#xD;
             tests:&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN), or if serum&#xD;
                  creatinine outside normal range, then glomerular filtration rate (GFR) &gt; 40&#xD;
                  mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal&#xD;
                  Disease (MDRD) equation.&#xD;
&#xD;
               -  Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's&#xD;
                  syndrome.&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 x&#xD;
                  ULN.&#xD;
&#xD;
               -  Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 500/μl and platelets ≥ 20000/μl (unsupported by&#xD;
                  transfusions).&#xD;
&#xD;
          -  Subject is suitable for oral administration of study drug.&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be of nonchildbearing potential:&#xD;
&#xD;
               -  Postmenopausal (defined as at least 1 year without any menses) prior to&#xD;
                  screening, or&#xD;
&#xD;
               -  Documented surgically sterile or status posthysterectomy (at least 1 month prior&#xD;
                  to screening)&#xD;
&#xD;
               -  Or, if of childbearing potential,&#xD;
&#xD;
               -  Agree not to try to become pregnant during the study and for 6 months after the&#xD;
                  final study drug administration&#xD;
&#xD;
               -  And have a negative urine or serum pregnancy test at screening&#xD;
&#xD;
               -  And, if heterosexually active, agree to consistently use highly effective&#xD;
                  contraception per locally accepted standards (in addition to a barrier method)&#xD;
                  starting at screening and throughout the study period and for 6 months after the&#xD;
                  final study drug administration.&#xD;
&#xD;
          -  Female subject must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 2 months and 1 week after the final study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 6 months after the final study drug administration.&#xD;
&#xD;
          -  Male subject and subject's female partners who are of childbearing potential must be&#xD;
             using highly effective contraception per locally accepted standards (in addition to a&#xD;
             barrier method) starting at screening and continue throughout the study period and for&#xD;
             4 months and 1 week after the final study drug administration.&#xD;
&#xD;
          -  Male subject must not donate sperm starting at screening and throughout the study&#xD;
             period and for 4 months and 1 week after the final study drug administration.&#xD;
&#xD;
          -  Subject agrees not to participate in another interventional study while on treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had prior allogeneic transplant.&#xD;
&#xD;
          -  Subject has QTcF interval &gt; 450 msec (average of triplicate determinations based on&#xD;
             central reading).&#xD;
&#xD;
          -  Subject with Long QT Syndrome.&#xD;
&#xD;
          -  Subject with hypokalemia and hypomagnesemia at screening (defined as values below&#xD;
             LLN).&#xD;
&#xD;
          -  Subject has clinically active central nervous system leukemia.&#xD;
&#xD;
          -  Subject is known to have human immunodeficiency virus infection.&#xD;
&#xD;
          -  Subject has active hepatitis B or C.&#xD;
&#xD;
          -  Subject has an uncontrolled infection. If a bacterial or viral infection is present,&#xD;
             the subject must be receiving definitive therapy and have no signs of progressing&#xD;
             infection for 72 hours prior to randomization. If a fungal infection is present, the&#xD;
             subject must be receiving definitive systemic anti-fungal therapy and have no signs of&#xD;
             progressing infection for 1 week prior to randomization.&#xD;
&#xD;
          -  Subject has progressing infection defined as hemodynamic instability attributable to&#xD;
             sepsis or new symptoms, worsening physical signs or radiographic findings attributable&#xD;
             to infection. Persisting fever without other signs or symptoms will not be interpreted&#xD;
             as progressing infection.&#xD;
&#xD;
          -  Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias,&#xD;
             electrocardiographic evidence of acute ischemia, congestive heart failure New York&#xD;
             Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart&#xD;
             failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated&#xD;
             acquisition (MUGA) scan performed within 1 month prior to study entry results in a&#xD;
             left ventricular ejection fraction that is ≥ 45%.&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that are strong inducers of&#xD;
             cytochrome P450 (CYP) 3A.&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that are strong inhibitors or&#xD;
             inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered&#xD;
             absolutely essential for the care of the subject.&#xD;
&#xD;
          -  Subject requires treatment with concomitant drugs that target serotonin&#xD;
             5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or&#xD;
             sigma nonspecific receptor with the exception of drugs that are considered absolutely&#xD;
             essential for the care of the subject.&#xD;
&#xD;
          -  Subject has a serious medical or psychiatric illness likely to interfere with&#xD;
             participation in this clinical study.&#xD;
&#xD;
          -  Subject has prior malignancies, except resected basal cell carcinoma or treated&#xD;
             cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously&#xD;
             will be allowed. Cancer treated with curative intent &lt; 5 years previously will not be&#xD;
             allowed.&#xD;
&#xD;
          -  Subject has any condition which makes the subject unsuitable for study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10017</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10030</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10012</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10025</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10007</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10029</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>26615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BR55002</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15001</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA15003</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42001</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45002</name>
      <address>
        <city>Arhus</city>
        <state>Region Midtjylland</state>
        <zip>DK 8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33004</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33002</name>
      <address>
        <city>Tours cedex 01</city>
        <state>Indre-et-Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33014</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33007</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Rhone</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33001</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33009</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33008</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49008</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GR30010</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GR30004</name>
      <address>
        <city>Thessaloniki</city>
        <state>Kentriki Makedonia</state>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GR30009</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GR30007</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36003</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>H-4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IL97205</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39011</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39004</name>
      <address>
        <city>Castelfranco Veneto (TV)</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39008</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39005</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39010</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39002</name>
      <address>
        <city>Roma</city>
        <zip>161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81018</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81025</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81002</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81024</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81012</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81004</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81009</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81014</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81023</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81011</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81010</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81017</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82005</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82014</name>
      <address>
        <city>Bucheon-Si</city>
        <state>Gyeonggido</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82013</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggido</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82008</name>
      <address>
        <city>Namdong</city>
        <state>Incheon Gwang'yeogsiv</state>
        <zip>405 760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82003</name>
      <address>
        <city>Hwasungun</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82012</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82006</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR82009</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001</name>
      <address>
        <city>Olsztyn</city>
        <state>Warmińsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48002</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48007</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35106</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35101</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40005</name>
      <address>
        <city>București</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38102</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46003</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SE46002</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88605</name>
      <address>
        <city>Kaohsiung</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88604</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW88603</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44007</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44019</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44006</name>
      <address>
        <city>Cottingham</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU165JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44018</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44002</name>
      <address>
        <city>Birmingham</city>
        <zip>B95SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44015</name>
      <address>
        <city>Cardiff</city>
        <zip>CF4 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44020</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44004</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>First Complete Remission</keyword>
  <keyword>gilteritinib</keyword>
  <keyword>FLT3/ITD</keyword>
  <keyword>AML</keyword>
  <keyword>ASP2215</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

